US competition authorities have approved a pair of major deals in the medical field, including Medtronic's purchase of Covidien.
The Federal Trade Commission said it would allow medical technology company Medtronic's $42.9 billion deal to buy Dublin-based Covidien on condition that it sell its drug-coated balloon catheter business.
The commission also approved two parts of a three-way deal between GlaxoSmithKline and Novartis, which reflects an industry trend in which companies focus on their strongest businesses.
The deal, announced in April, calls for Britain's GSK to buy most of the vaccines business of Novartis, the Swiss company to purchase GSK's cancer drugs, and the two groups to team up in consumer healthcare.
The FTC approved the vaccines portion of the deal and the consumer healthcare part on the condition that Novartis sell its Habitrol nicotine patch, the companies said yesterday.
Novartis and GSK, which has Nicoderm CQ, are two of only three companies that sell nicotine patches to US retailers, the FTC said.
The FTC's approval of the Covidien deal takes Minnesota-based Medtronic a step closer to moving to Ireland, where it could have access to revenues earned outside the US without paying US taxes on them.
The merger, which was announced in June, will create a company close in size to the medical device business of industry leader Johnson & Johnson.
The European Union and China must still approve the deal, while Canada approved it during the week, Medtronic said.
Medtronic, which makes defibrillators, spinal implants, insulin pumps and other products, said previously that it expected the deal to close in early 2015.
It is the world's largest stand-alone medical device maker, with a market value of more than $60 billion, while Covidien's products are used in a range of surgical procedures.
Colorado-based Spectranetics will purchase Covidien's drug-coated catheter business, the FTC said.
